PubRank

J Dillner

Author PubWeight™ 148.19‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001 6.33
2 Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001 5.99
3 Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001 3.28
4 JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 2008 3.06
5 Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996 2.83
6 Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999 2.79
7 Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol 1987 2.55
8 Strategies for global control of cervical cancer. Int J Cancer 1995 2.52
9 An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc Natl Acad Sci U S A 1986 2.42
10 Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A 1984 2.40
11 Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A 1986 2.34
12 Penile cancer: epidemiology, pathogenesis and prevention. World J Urol 2008 2.14
13 Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst 1995 2.01
14 BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci U S A 1988 1.91
15 Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005 1.70
16 Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 2000 1.58
17 Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ 1997 1.55
18 Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. BMJ 1996 1.51
19 Antibodies against synthetic peptides react with the second Epstein-Barr virus-associated nuclear antigen. EMBO J 1985 1.48
20 No serological evidence for non-sexual spread of HPV16. Lancet 1994 1.47
21 A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 1997 1.42
22 An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004 1.40
23 Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 1998 1.39
24 Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA. Int J Cancer 1985 1.38
25 HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer 2007 1.30
26 Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol 1999 1.26
27 Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer 2007 1.25
28 Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. J Infect Dis 1990 1.25
29 Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. J Clin Virol 2001 1.23
30 A novel and rapid PCR-based method for genotyping human papillomaviruses in clinical samples. J Clin Microbiol 2000 1.23
31 Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol 2001 1.20
32 Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer 2002 1.20
33 Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol 1999 1.16
34 Identification of human papillomavirus seroconversions. J Gen Virol 1995 1.14
35 Combined effect of smoking and human papillomavirus type 16 infection in cervical carcinogenesis. Epidemiology 1998 1.13
36 Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. J Natl Cancer Inst 1999 1.11
37 Lymphoblastoid cell lines and Burkitt-lymphoma-derived cell lines differ in the expression of a second Epstein-Barr virus encoded nuclear antigen. Int J Cancer 1986 1.10
38 Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol 1996 1.09
39 Induction of bovine papillomavirus E2 gene expression and early region transcription by cell growth arrest: correlation with viral DNA amplification and evidence for differential promoter induction. J Virol 1990 1.08
40 Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies--a prospective study. Cancer Causes Control 1993 1.07
41 Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol 1999 1.06
42 Correlates of the spread of human papillomavirus infection. Cancer Epidemiol Biomarkers Prev 2000 1.06
43 Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer 2000 1.06
44 A prospective, seroepidemiological study of the role of human papillomavirus in esophageal cancer in Norway. Cancer Res 1997 1.05
45 Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. Virology 1995 1.05
46 Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969-1989. Int J Cancer 1998 1.04
47 Down-regulation of the EBV-encoded membrane protein (LMP) in Burkitt lymphomas. Int J Cancer 1987 1.03
48 Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors. J Clin Microbiol 1991 1.03
49 A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int J Cancer 1996 1.03
50 Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 1996 1.03
51 Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden. Cancer Epidemiol Biomarkers Prev 2000 1.02
52 Structural analysis of the human papillomavirus type 16-E2 transactivator with antipeptide antibodies reveals a high mobility region linking the transactivation and the DNA-binding domains. Nucleic Acids Res 1991 1.01
53 The disease associations of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes. J Gen Virol 1995 1.00
54 Combined effect of low-penetrant SNPs on breast cancer risk. Br J Cancer 2011 1.00
55 Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Genitourin Med 1997 0.99
56 Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. J Gen Virol 2007 0.99
57 A population-based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol 2000 0.98
58 Nuclear DNA-binding proteins determined by the Epstein-Barr virus-related simian lymphotropic herpesviruses H. gorilla, H. pan, H. pongo and H. papio. J Gen Virol 1987 0.97
59 No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer 1999 0.97
60 Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses. J Virol 1991 0.96
61 The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. J Eur Acad Dermatol Venereol 2009 0.95
62 Reactivity to human papillomavirus type 16 L1 virus-like particles in sera from patients with genital cancer and patients with carcinomas at five different extragenital sites. Br J Cancer 2003 0.95
63 Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. Int J Cancer 1990 0.94
64 A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children. Int J Cancer 1999 0.94
65 The Epstein-Barr virus determined nuclear antigen is composed of at least three different antigens. Int J Cancer 1986 0.92
66 Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br J Cancer 1999 0.92
67 Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes. J Gen Virol 1995 0.91
68 Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. Eur J Cancer 2004 0.91
69 Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. J Infect Dis 2000 0.91
70 Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection. Sex Transm Infect 1998 0.89
71 A population-based cohort study of KIR genes and genotypes in relation to cervical intraepithelial neoplasia. Tissue Antigens 2005 0.89
72 Molecular and serological studies of human papillomavirus among patients with anal epidermoid carcinoma. Int J Cancer 1993 0.89
73 Immunity to oncogenic human papillomaviruses. Adv Cancer Res 2001 0.89
74 Introduction of human papillomavirus (HPV) vaccination in Sweden. Euro Surveill 2009 0.88
75 Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser. Am J Obstet Gynecol 2000 0.88
76 Human serum antibodies to a major defined epitope of human herpesvirus 8 small viral capsid antigen. J Infect Dis 1999 0.88
77 Isolation, partial characterization, and molecular cloning of a human colon adenocarcinoma cell-surface glycoprotein recognized by the C215 mouse monoclonal antibody. J Biol Chem 1993 0.88
78 A population-based study of human papillomavirus deoxyribonucleic acid testing for predicting cervical intraepithelial neoplasia. Am J Obstet Gynecol 1998 0.87
79 Different HLA-DR-DQ haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type-16 seropositive and seronegative Swedish women. Int J Cancer 1996 0.87
80 Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions. Cancer Epidemiol Biomarkers Prev 1997 0.87
81 Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. J Gen Virol 1999 0.87
82 A prospective study of the relationship between prediagnostic human papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas. Br J Cancer 2002 0.87
83 Tumor necrosis factor A and MHC class I chain related gene A (MIC-A) polymorphisms in Swedish patients with cervical cancer. Hum Immunol 2001 0.86
84 Prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection. J Med Virol 1995 0.85
85 Levels of immunoglobulin G antibodies against defined epitopes of the L1 and L2 capsid proteins of human papillomavirus type 6 are elevated in men with a history of condylomata acuminata. J Clin Microbiol 1992 0.84
86 Herpes simplex virus and human papillomavirus in a population-based case-control study of cervical intraepithelial neoplasia grade II-III. APMIS 1998 0.84
87 HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1. Int Immunol 1995 0.84
88 Scanning the structure and antigenicity of HPV-16 E6 and E7 oncoproteins using antipeptide antibodies. Oncogene 1994 0.84
89 Characterization of the complete genomes of Camelus dromedarius papillomavirus types 1 and 2. J Gen Virol 2011 0.83
90 Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland. Br J Cancer 2013 0.83
91 Seroepidemiology as basis for design of a human papillomavirus vaccination program. Vaccine 2008 0.83
92 Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA. J Clin Microbiol 1996 0.82
93 No evidence of enteroviruses in the intestine of patients with type 1 diabetes. Diabetologia 2012 0.82
94 Molecular size variation of EBNA is determined by the EB viral genome. Intervirology 1984 0.82
95 Preventive human papillomavirus vaccination. Sex Transm Infect 2002 0.82
96 A seroepidemiologic study of HPV infection and incident cervical squamous intraepithelial lesions. Viral Immunol 1994 0.82
97 Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein. J Gen Virol 1997 0.81
98 Risk of second cancers after the diagnosis of Merkel cell carcinoma in Scandinavia. Br J Cancer 2010 0.81
99 A prospective study of antibody responses to defined epitopes of human papillomavirus (HPV) type 16 in relationship to genital and anorectal presence of HPV DNA. Clin Diagn Lab Immunol 1994 0.81
100 Antibodies against papillomavirus antigens in cervical secretions from condyloma patients. J Clin Microbiol 1993 0.81
101 A population-based case-control study of human papillomavirus-type-16 seropositivity and incident high-grade dysplasia of the uterine cervix. Int J Cancer 1996 0.81
102 Seropositivity to human herpesvirus 8 in relation to sexual history and risk of sexually transmitted infections among women. Int J Cancer 2000 0.80
103 Serological responses to papillomavirus group-specific antigens in women with neoplasia of the cervix uteri. J Clin Microbiol 1990 0.80
104 Predominance of serum antibodies to synthetic peptide stemming from HPV 18 open reading frame E2 in cervical adenocarcinoma. J Clin Pathol 1992 0.80
105 Antibodies against human papillomavirus type 6 capsids are elevated in men with previous condylomas. APMIS 1997 0.79
106 Primary induction of human cytotoxic lymphocytes against a synthetic peptide of the human immunodeficiency virus type 1 protease. J Gen Virol 1997 0.79
107 Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination. Sex Transm Infect 2000 0.79
108 A prospective seroepidemiological study of human herpesvirus-8 infection and the risk of multiple myeloma. Br J Cancer 2001 0.79
109 Joint Nordic prospective study on human herpesvirus 8 and multiple myeloma risk. Br J Cancer 2005 0.79
110 False-positive prostate cancer markers in a man with symptomatic urethral Chlamydia trachomatis infection. Int J STD AIDS 2013 0.78
111 Evaluation of serum antibody response to a newly identified B-cell epitope in the minor nucleocapsid protein L2 of human papillomavirus type 16. Clin Diagn Virol 1993 0.78
112 Laboratory diagnosis of human herpesvirus 8 infection in humans. Eur J Clin Microbiol Infect Dis 2002 0.78
113 Seropositivity to multiple sexually transmitted infections is not common. Sex Transm Dis 2000 0.78
114 Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment, and survival in carcinoma of the uterine cervix. Cancer Immunol Immunother 1995 0.78
115 Poor antibody response against human papillomavirus in adult-onset laryngeal papillomatosis. J Med Microbiol 2001 0.78
116 Squamous cell carcinoma of the penis: premalignant lesions. Scand J Urol Nephrol Suppl 2000 0.77
117 Epstein-Barr virus (EBV) antigen-specific leukocyte migration inhibition (LMI) in infectious mononucleosis (IM). I. Kinetics and response to a membrane protein on EBV-transformed cells. Clin Immunol Immunopathol 1986 0.77
118 Antibody responses to defined epitopes in the Epstein-Barr virus BZLF1-encoded transactivator protein among human immunodeficiency virus-infected patients. Clin Diagn Lab Immunol 1996 0.77
119 Low levels of serum vitamins A and E in blood and subsequent risk for cervical cancer: interaction with HPV seropositivity. Nutr Cancer 1999 0.77
120 Detection of adeno-associated virus type 2 genome in cervical carcinoma. Br J Cancer 2006 0.77
121 Antibodies in human sera against the Epstein-Barr virus encoded latent membrane protein (LMP). Immunol Lett 1988 0.76
122 Human papillomavirus antibody responses among patients with incident cervical carcinoma. J Med Virol 1997 0.76
123 Epstein-Barr virus (EBV) antigen-specific leukocyte migration inhibition in infectious mononucleosis. II. Kinetics of sensitization against five EBV-encoded nuclear proteins and the latent membrane protein. Clin Immunol Immunopathol 1989 0.76
124 MICA gene polymorphism and the risk to develop cervical intraepithelial neoplasia. Hum Immunol 1999 0.76
125 Disappearance of antibodies to HPV 16 E7 after treatment for cervical cancer. Lancet 1993 0.75
126 Salivary sIgA response in HIV-1 infection. J Acquir Immune Defic Syndr 1999 0.75
127 Serum p53 accumulation and altered antibody responses to Epstein-Barr virus proteins precede diagnosis of haemopoietic malignancies of lymphoid origin. Br J Haematol 1996 0.75
128 Vaccinating women against premature death: summary of an International Workshop, Helsinki, Finland, 10.01.2000. Vaccine 2001 0.75
129 Epstein-Barr virus gene expression during primary B-lymphocyte infection, in transformed and Burkitt lymphoma-derived cell lines. Curr Top Microbiol Immunol 1986 0.75
130 No evidence of HPV in epidemic and endemic Kaposi's sarcoma. J Acquir Immune Defic Syndr 1993 0.75
131 [Sexuality and STD infections among teenage girls. "Unprotected sex" is common in spite of sufficient knowledge about the risks]. Lakartidningen 1997 0.75
132 A two-site enzyme immunoassay for quantitation of human papillomavirus type 16 particles. J Virol Methods 1995 0.75
133 Comparable strategies needed to evaluate human papillomavirus vaccine efficiency across Europe. Euro Surveill 2006 0.75
134 Seroepidemiology of human papillomavirus type 73: a sexually transmitted low-risk virus. Int J Cancer 2000 0.75
135 Linear epitopes of the replication-activator protein of Epstein-Barr virus recognised by specific serum IgG in nasopharyngeal carcinoma. Cancer Immunol Immunother 1995 0.75
136 Serological responses to human papillomavirus type 16 antigens in women before and after renal transplantation. J Med Virol 1993 0.75
137 Screening for nasopharyngeal carcinoma with an ELISA using the Epstein-Barr virus nuclear antigen, EBNA 1: a complementary test to the IgA/VCA immunofluorescence assay. J Virol Methods 1993 0.75